benzylisoquinoline alkaloid - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	benzylisoquinoline alkaloid	go back to main search page
Accession:	CHEBI:22750	browse the term
Definition:	Any isoquinoline alkaloid based on a benzylisoquinoline skeleton.
Synonyms:	related_synonym:	benzylisoquinoline alkaloids

show annotations for term's descendants Sort by:
Rat (223) Mouse (223) Human (224) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (1) Green Monkey (0) Naked Mole-rat (0) All
Genes (223)

(+)-Tetrandrine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity
decreases expression

tetrandrine results in decreased activity of ABCB1A protein
tetrandrine results in decreased expression of ABCB1

PMID:17273824 PMID:19840446

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

G

actin alpha 2, smooth muscle

multiple interactions

tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 mRNA]; tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 protein]; tetrandrine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

aryl hydrocarbon receptor

multiple interactions

AHR protein affects the reaction [tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein]; AHR protein affects the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568

G

apoptosis inducing factor, mitochondria associated 1

increases expression

tetrandrine results in increased expression of AIFM1 protein

NCBI chr X:132,528,107...132,567,237
Ensembl chr X:127,650,226...127,689,256

G

AKT serine/threonine kinase 1

increases phosphorylation
decreases phosphorylation

tetrandrine results in increased phosphorylation of AKT1 protein
tetrandrine results in decreased phosphorylation of AKT1 protein

PMID:30549224 PMID:31255635

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

autophagy related 12

increases expression

tetrandrine results in increased expression of ATG12 protein

NCBI chr18:41,638,841...41,649,311
Ensembl chr18:39,452,191...39,462,418

G

autophagy related 5

increases expression
decreases expression

tetrandrine results in increased expression of ATG5 protein
tetrandrine results in decreased expression of ATG5 protein

PMID:25266202 PMID:26822499

NCBI chr20:49,380,835...49,471,826
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

decreases expression

tetrandrine results in decreased expression of ATG7 protein

NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:147,718,752...147,925,593

G

BCL2-antagonist/killer 1

increases expression

tetrandrine results in increased expression of BAK1 protein

NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

increases expression

tetrandrine results in increased expression of BAX protein

PMID:26822499 PMID:31255635

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

affects response to substance
increases expression
multiple interactions
decreases expression

BCL2 protein affects the susceptibility to tetrandrine
tetrandrine results in increased expression of BCL2 protein
CYP3A5 protein promotes the reaction [tetrandrine results in decreased expression of BCL2 protein]
tetrandrine results in decreased expression of BCL2 mRNA; tetrandrine results in decreased expression of BCL2 protein

PMID:18495333 PMID:26302866 PMID:26822499 PMID:31255635

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression

tetrandrine results in decreased expression of BCL2L1 protein

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

beclin 1

increases expression
multiple interactions
decreases expression

tetrandrine results in increased expression of BECN1 protein
[sodium arsenite co-treated with tetrandrine] results in increased expression of BECN1 protein
tetrandrine results in decreased expression of BECN1 protein

PMID:25266202 PMID:26822499 PMID:30123091

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,231,388...86,246,742

G

BH3 interacting domain death agonist

decreases expression

tetrandrine results in decreased expression of BID protein

NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:154,113,198...154,134,720

G

baculoviral IAP repeat-containing 5

affects binding
decreases expression

tetrandrine binds to BIRC5 promoter
tetrandrine results in decreased expression of BIRC5 mRNA

PMID:17968851 PMID:18495333

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380

G

caspase 12

increases cleavage

tetrandrine results in increased cleavage of CASP12 protein

NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:2,642,434...2,674,037

G

caspase 3

increases expression
increases cleavage
multiple interactions

tetrandrine results in increased expression of CASP3 protein
tetrandrine results in increased cleavage of CASP3 protein
3-methyladenine inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; CYP3A5 protein promotes the reaction [tetrandrine results in increased expression of CASP3 protein]; tetrandrine results in increased cleavage of and results in increased activity of CASP3 protein

PMID:25266202 PMID:26302866 PMID:26822499 PMID:31255635

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
increases expression
increases cleavage

tetrandrine results in increased cleavage of and results in increased activity of CASP8 protein
tetrandrine results in increased expression of CASP8 protein
tetrandrine results in increased cleavage of CASP8 protein

PMID:25266202 PMID:26822499 PMID:31255635

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases cleavage

tetrandrine results in increased cleavage of and results in increased activity of CASP9 protein
tetrandrine results in increased cleavage of CASP9 protein

PMID:25266202 PMID:26822499

Ensembl chr 5:154,109,046...154,126,626

G

cyclin A2

increases expression

tetrandrine results in increased expression of CCNA2 protein

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

increases expression

tetrandrine results in increased expression of CCNB1 protein

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

multiple interactions
decreases expression
affects expression

[sodium arsenite co-treated with tetrandrine] affects the expression of CCND1 protein; [sodium arsenite co-treated with tetrandrine] results in decreased expression of CCND1 protein
tetrandrine results in decreased expression of CCND1 protein
tetrandrine affects the expression of CCND1 protein

PMID:30123091 PMID:31255635

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602

G

cadherin 1

decreases expression

tetrandrine results in decreased expression of CDH1 protein

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

decreases expression

tetrandrine results in decreased expression of CDH2 protein

NCBI chr18:8,051,097...8,265,288
Ensembl chr18:7,776,704...7,990,167

G

cyclin-dependent kinase inhibitor 1A

increases expression
affects expression
multiple interactions

tetrandrine results in increased expression of CDKN1A
tetrandrine affects the expression of CDKN1A protein
[sodium arsenite co-treated with tetrandrine] affects the expression of CDKN1A protein

PMID:19840446 PMID:30123091

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression

[sodium arsenite co-treated with tetrandrine] results in increased expression of CDKN1B protein
tetrandrine results in increased expression of CDKN1B protein

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]; tetrandrine inhibits the reaction [TNF protein results in increased expression of CHUK protein]

PMID:17201889 PMID:22001142

NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:242,959,760...242,995,065

G

collagen type I alpha 1 chain

decreases expression

tetrandrine results in decreased expression of COL1A1 mRNA

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624

G

collagen type II alpha 1 chain

multiple interactions

[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein; [tetrandrine co-treated with COL2A1 protein] results in increased expression of FOXP3 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein]; resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]]; resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IFNG protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL1B protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL6 protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of RORC mRNA]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]

NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:129,098,786...129,127,546

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein; AHR protein affects the reaction [tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein]; AHR protein affects the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]; Dactinomycin inhibits the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]; Dactinomycin inhibits the reaction [tetrandrine results in increased expression of CYP1A1 protein]; Resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA]; Resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein]; tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases glutathionylation

CYP3A4 protein results in increased glutathionylation of tetrandrine

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases glutathionylation
increases response to substance
multiple interactions

CYP3A5 protein results in increased glutathionylation of tetrandrine
CYP3A5 protein results in increased susceptibility to tetrandrine
CYP3A5 protein promotes the reaction [tetrandrine results in decreased abundance of Glutathione]; CYP3A5 protein promotes the reaction [tetrandrine results in decreased expression of BCL2 protein]; CYP3A5 protein promotes the reaction [tetrandrine results in increased abundance of Reactive Oxygen Species]; CYP3A5 protein promotes the reaction [tetrandrine results in increased expression of CASP3 protein]

PMID:21992520 PMID:26302866

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:16,806,207...16,846,422

G

DNA-damage inducible transcript 3

increases expression

tetrandrine results in increased expression of DDIT3 protein

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

epidermal growth factor receptor

decreases phosphorylation

tetrandrine results in decreased phosphorylation of EGFR protein

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382

G

endonuclease G

decreases expression

tetrandrine results in decreased expression of ENDOG protein

NCBI chr 3:33,846,935...33,849,531
Ensembl chr 3:13,449,086...13,451,932

G

erb-b2 receptor tyrosine kinase 2

multiple interactions
decreases expression

[arsenite co-treated with tetrandrine] results in decreased expression of ERBB2 protein
tetrandrine results in decreased expression of ERBB2 protein

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,411,313...83,435,078

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

tetrandrine inhibits the reaction [Hexachlorocyclohexane results in increased expression of FOS mRNA]

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box O3

multiple interactions

[sodium arsenite co-treated with tetrandrine] affects the expression of and affects the phosphorylation of FOXO3 protein; [sodium arsenite co-treated with tetrandrine] results in increased expression of FOXO3 protein; tetrandrine affects the expression of and affects the phosphorylation of FOXO3 protein

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:45,672,995...45,764,561

G

forkhead box P3

multiple interactions
increases expression

[tetrandrine co-treated with COL2A1 protein] results in increased expression of FOXP3 mRNA; alpha-naphthoflavone inhibits the reaction [tetrandrine results in increased expression of FOXP3 mRNA]; resveratrol inhibits the reaction [tetrandrine results in increased expression of FOXP3 mRNA]

NCBI chr X:17,580,380...17,601,181
Ensembl chr X:14,908,494...14,923,838

G

growth factor receptor bound protein 2

decreases expression

tetrandrine results in decreased expression of GRB2 protein

NCBI chr10:101,380,354...101,448,138
Ensembl chr10:100,869,718...100,949,309

G

glycogen synthase kinase 3 beta

decreases expression

tetrandrine results in decreased expression of GSK3B protein modified form

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646

G

heat shock protein family A (Hsp70) member 5

increases expression

tetrandrine results in increased expression of HSPA5 protein

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891

G

intercellular adhesion molecule 1

multiple interactions
increases expression

tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ICAM1 mRNA]; tetrandrine inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]
tetrandrine results in increased expression of ICAM1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one affects the reaction [[arsenite co-treated with tetrandrine] affects the expression of ICAM1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [tetrandrine results in increased expression of ICAM1 protein]; [arsenite co-treated with tetrandrine] affects the expression of ICAM1 protein; [arsenite co-treated with tetrandrine] results in increased expression of ICAM1 protein

PMID:17201889 PMID:31934280

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438

G

interferon gamma

multiple interactions

tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IFNG protein]

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions
increases expression

[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein; alpha-naphthoflavone inhibits the reaction [tetrandrine results in increased expression of IL10 mRNA]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein]; resveratrol inhibits the reaction [tetrandrine results in increased expression of IL10 mRNA]

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313

G

interleukin 17A

multiple interactions
decreases expression

resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]
tetrandrine results in decreased expression of IL17A mRNA

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 beta

multiple interactions

tetrandrine inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of MMP9 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]
tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL1B protein]

PMID:22001142 PMID:26640276

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases phosphorylation

tetrandrine results in decreased phosphorylation of JUN protein

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656

G

lamin A/C

increases expression

tetrandrine results in increased expression of LMNA protein

NCBI chr 2:176,237,564...176,265,301
Ensembl chr 2:173,939,751...173,960,423

G

microtubule-associated protein 1 light chain 3 beta

increases expression

tetrandrine results in increased expression of MAP1LC3B

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]
tetrandrine results in increased phosphorylation of MAPK1 protein
[arsenite co-treated with tetrandrine] results in increased phosphorylation of MAPK1 protein; arsenite promotes the reaction [tetrandrine results in increased phosphorylation of MAPK1 protein]; tetrandrine promotes the reaction [arsenite results in increased phosphorylation of MAPK1 protein]

PMID:22001142 PMID:31934280

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]
tetrandrine results in increased phosphorylation of MAPK3 protein
[arsenite co-treated with tetrandrine] results in increased phosphorylation of MAPK3 protein; arsenite promotes the reaction [tetrandrine results in increased phosphorylation of MAPK3 protein]; tetrandrine promotes the reaction [arsenite results in increased phosphorylation of MAPK3 protein]

PMID:22001142 PMID:31934280

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

MCL1 apoptosis regulator, BCL2 family member

increases expression

tetrandrine results in increased expression of MCL1 protein

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:183,219,220...183,222,303

G

matrix metallopeptidase 2

multiple interactions

tetrandrine results in decreased expression of and results in decreased activity of MMP2 protein

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

multiple interactions
decreases expression

tetrandrine inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of MMP9 protein]
tetrandrine results in decreased expression of MMP9 protein

PMID:22001142 PMID:30549224

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

multiple interactions
decreases expression

[sodium arsenite co-treated with tetrandrine] affects the expression of and affects the phosphorylation of MTOR protein; tetrandrine affects the expression of and affects the phosphorylation of MTOR protein; tetrandrine results in decreased expression of and results in decreased phosphorylation of MTOR protein
tetrandrine results in decreased expression of MTOR protein; tetrandrine results in decreased expression of MTOR protein modified form

PMID:25266202 PMID:26822499 PMID:30123091 PMID:31255635

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311

G

NFKB inhibitor alpha

multiple interactions

tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; tetrandrine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]

PMID:17201889 PMID:22001142

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

tetrandrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210

G

poly (ADP-ribose) polymerase 1

increases cleavage

tetrandrine results in increased cleavage of PARP1 protein

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

protein kinase AMP-activated catalytic subunit alpha 1

affects phosphorylation
multiple interactions

tetrandrine affects the phosphorylation of PRKAA1 protein
[sodium arsenite co-treated with tetrandrine] affects the phosphorylation of PRKAA1 protein

NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:54,240,137...54,275,978

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases phosphorylation

tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased localization of RELA protein]; tetrandrine inhibits the reaction [TNF protein results in increased localization of RELA protein]
tetrandrine results in decreased expression of and results in decreased activity of RELA protein
tetrandrine results in increased phosphorylation of RELA protein

PMID:17201889 PMID:30549224 PMID:31255635

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484

G

RAR-related orphan receptor C

multiple interactions
decreases expression

tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of RORC mRNA]
tetrandrine results in decreased expression of RORC mRNA

NCBI chr 2:184,698,779...184,723,942
Ensembl chr 2:182,009,286...182,034,907

G

ribosomal protein S6

decreases expression

tetrandrine results in decreased expression of RPS6 protein modified form

NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

regulatory associated protein of MTOR, complex 1

decreases expression

tetrandrine results in decreased expression of RAPTOR protein

NCBI chr10:105,376,943...105,675,416
Ensembl chr10:104,878,487...105,176,983

G

stratifin

increases expression

tetrandrine results in increased expression of SFN protein

NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:145,826,201...145,831,314

G

snail family transcriptional repressor 1

decreases expression

tetrandrine results in decreased expression of SNAI1 protein

NCBI chr 3:176,667,476...176,671,965
Ensembl chr 3:156,248,485...156,252,969

G

SOS Ras/Rac guanine nucleotide exchange factor 1

decreases expression

tetrandrine results in decreased expression of SOS1 protein

NCBI chr 6:20,286,117...20,363,350
Ensembl chr 6:14,533,360...14,611,107

G

sequestosome 1

decreases expression

tetrandrine results in decreased expression of SQSTM1 protein

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673

G

transforming growth factor, beta 1

multiple interactions

tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]; tetrandrine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

tetrandrine inhibits the reaction [TNF protein results in increased expression of CHUK protein]; tetrandrine inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; tetrandrine inhibits the reaction [TNF protein results in increased localization of RELA protein]; tetrandrine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]
resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]

PMID:17201889 PMID:26640276

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

unc-51 like autophagy activating kinase 1

increases phosphorylation
decreases expression

tetrandrine results in increased phosphorylation of ULK1 protein
tetrandrine results in decreased expression of ULK1 protein

PMID:25266202 PMID:26822499

NCBI chr12:51,511,492...51,537,746
Ensembl chr12:45,851,710...45,877,966

(-)-noscapine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

Noscapine promotes the reaction [Cisplatin results in increased expression of BAX protein]
Noscapine results in increased expression of BAX protein

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

Noscapine results in decreased expression of BCL2 protein
Noscapine promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

baculoviral IAP repeat-containing 5

decreases response to substance
increases expression
decreases expression
multiple interactions

BIRC5 protein results in decreased susceptibility to Noscapine
Noscapine results in increased expression of BIRC5 mRNA; Noscapine results in increased expression of BIRC5 protein
Noscapine results in decreased expression of BIRC5 protein
Noscapine promotes the reaction [Cisplatin results in decreased expression of BIRC5 protein]

PMID:20674069 PMID:22848370

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380

G

caspase 3

multiple interactions
increases activity

[Noscapine co-treated with Cisplatin] results in increased cleavage of CASP3 protein; Noscapine promotes the reaction [Cisplatin results in increased expression of and results in increased cleavage of CASP3 protein]; Noscapine results in increased expression of and results in increased cleavage of CASP3 protein
Noscapine results in increased activity of CASP3 protein

PMID:20674069 PMID:22848370

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

Noscapine promotes the reaction [Cisplatin results in increased expression of and results in increased cleavage of CASP9 protein]; Noscapine results in increased expression of and results in increased cleavage of CASP9 protein

Ensembl chr 5:154,109,046...154,126,626

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

Noscapine promotes the reaction [Cisplatin results in increased expression of CDKN1A protein]
Noscapine results in increased expression of CDKN1A protein

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Noscapine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

Noscapine results in increased degradation of and results in decreased expression of and results in decreased activity of HIF1A protein

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261

G

poly (ADP-ribose) polymerase 1

increases cleavage

Noscapine results in increased cleavage of PARP1 protein

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

solute carrier family 22 member 2

multiple interactions

Noscapine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:48,121,061...48,163,268

G

tumor protein p53

multiple interactions
increases expression

Noscapine promotes the reaction [Cisplatin results in increased expression of TP53 protein]; Noscapine results in increased expression of and results in increased phosphorylation of TP53 protein
Noscapine results in increased expression of TP53 protein

PMID:20674069 PMID:22848370

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

vascular endothelial growth factor A

decreases secretion

Noscapine results in decreased secretion of VEGFA protein

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641

(RS)-coclaurine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 4

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA

NCBI chr 4:26,106,895...26,164,440
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595

G

aldolase, fructose-bisphosphate C

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ALDOA mRNA

NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,217,451...63,221,066

G

arginine vasopressin receptor 1A

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA

NCBI chr 7:59,999,743...60,003,667
Ensembl chr 7:58,114,284...58,122,215

G

betaine-homocysteine S-methyltransferase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA

NCBI chr 2:26,594,852...26,614,429
Ensembl chr 2:24,859,873...24,879,742

G

cyclin G1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA

NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,176,234...25,181,641

G

CD36 molecule

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA

NCBI chr 4:18,209,088...18,302,142
Ensembl chr 4:17,354,466...17,513,903

G

cell division cycle 14B

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA

NCBI chr17:850,272...938,972
Ensembl chr17:844,685...933,235

G

cell migration inducing hyaluronidase 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA

NCBI chr 1:228,756,826...228,834,313
Ensembl chr 1:219,337,985...219,407,760

G

C-X-C motif chemokine ligand 12

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA

NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312

G

fatty acid synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544

G

glutathione-disulfide reductase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661

G

lipoprotein lipase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249

G

lanosterol synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA

NCBI chr20:12,090,641...12,118,230
Ensembl chr20:12,092,774...12,118,762

G

microRNA 101a

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA

NCBI chr 5:121,081,683...121,081,757
Ensembl chr 5:115,966,328...115,966,410

G

microRNA 122

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA

NCBI chr18:61,028,817...61,028,901

G

microRNA 192

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA

NCBI chr 1:212,994,209...212,994,318
Ensembl chr 1:203,564,946...203,565,055

G

MLX interacting protein-like

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA

NCBI chr12:27,178,158...27,213,675
Ensembl chr12:21,543,576...21,577,112

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

phospholipase A2, group XIIA

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA

NCBI chr 2:221,110,722...221,126,966
Ensembl chr 2:218,436,513...218,452,740

G

stearoyl-CoA desaturase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

G

thyroid hormone responsive

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA

NCBI chr 1:161,134,640...161,138,964
Ensembl chr 1:151,723,086...151,728,075

G

thioredoxin reductase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:20,830,045...20,907,863

(RS)-norcoclaurine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 4

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA

NCBI chr 4:26,106,895...26,164,440
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595

G

aldolase, fructose-bisphosphate C

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ALDOA mRNA

NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,217,451...63,221,066

G

arginine vasopressin receptor 1A

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA

NCBI chr 7:59,999,743...60,003,667
Ensembl chr 7:58,114,284...58,122,215

G

betaine-homocysteine S-methyltransferase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA

NCBI chr 2:26,594,852...26,614,429
Ensembl chr 2:24,859,873...24,879,742

G

cyclin G1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA

NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,176,234...25,181,641

G

CD36 molecule

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA

NCBI chr 4:18,209,088...18,302,142
Ensembl chr 4:17,354,466...17,513,903

G

cell division cycle 14B

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA

NCBI chr17:850,272...938,972
Ensembl chr17:844,685...933,235

G

cell migration inducing hyaluronidase 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA

NCBI chr 1:228,756,826...228,834,313
Ensembl chr 1:219,337,985...219,407,760

G

C-X-C motif chemokine ligand 12

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA

NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312

G

fatty acid synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544

G

glutathione-disulfide reductase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661

G

lipoprotein lipase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249

G

lanosterol synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA

NCBI chr20:12,090,641...12,118,230
Ensembl chr20:12,092,774...12,118,762

G

microRNA 101a

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA

NCBI chr 5:121,081,683...121,081,757
Ensembl chr 5:115,966,328...115,966,410

G

microRNA 122

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA

NCBI chr18:61,028,817...61,028,901

G

microRNA 192

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA

NCBI chr 1:212,994,209...212,994,318
Ensembl chr 1:203,564,946...203,565,055

G

MLX interacting protein-like

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA

NCBI chr12:27,178,158...27,213,675
Ensembl chr12:21,543,576...21,577,112

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

phospholipase A2, group XIIA

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA

NCBI chr 2:221,110,722...221,126,966
Ensembl chr 2:218,436,513...218,452,740

G

stearoyl-CoA desaturase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

G

thyroid hormone responsive

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA

NCBI chr 1:161,134,640...161,138,964
Ensembl chr 1:151,723,086...151,728,075

G

thioredoxin reductase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:20,830,045...20,907,863

(S)-coclaurine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 4

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA

NCBI chr 4:26,106,895...26,164,440
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595

G

aldolase, fructose-bisphosphate C

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ALDOA mRNA

NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,217,451...63,221,066

G

arginine vasopressin receptor 1A

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA

NCBI chr 7:59,999,743...60,003,667
Ensembl chr 7:58,114,284...58,122,215

G

betaine-homocysteine S-methyltransferase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA

NCBI chr 2:26,594,852...26,614,429
Ensembl chr 2:24,859,873...24,879,742

G

cyclin G1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA

NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,176,234...25,181,641

G

CD36 molecule

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA

NCBI chr 4:18,209,088...18,302,142
Ensembl chr 4:17,354,466...17,513,903

G

cell division cycle 14B

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA

NCBI chr17:850,272...938,972
Ensembl chr17:844,685...933,235

G

cell migration inducing hyaluronidase 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA

NCBI chr 1:228,756,826...228,834,313
Ensembl chr 1:219,337,985...219,407,760

G

C-X-C motif chemokine ligand 12

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA

NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312

G

fatty acid synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544

G

glutathione-disulfide reductase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661

G

lipoprotein lipase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249

G

lanosterol synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA

NCBI chr20:12,090,641...12,118,230
Ensembl chr20:12,092,774...12,118,762

G

microRNA 101a

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA

NCBI chr 5:121,081,683...121,081,757
Ensembl chr 5:115,966,328...115,966,410

G

microRNA 122

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA

NCBI chr18:61,028,817...61,028,901

G

microRNA 192

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA

NCBI chr 1:212,994,209...212,994,318
Ensembl chr 1:203,564,946...203,565,055

G

MLX interacting protein-like

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA

NCBI chr12:27,178,158...27,213,675
Ensembl chr12:21,543,576...21,577,112

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

phospholipase A2, group XIIA

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA

NCBI chr 2:221,110,722...221,126,966
Ensembl chr 2:218,436,513...218,452,740

G

stearoyl-CoA desaturase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

G

thyroid hormone responsive

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA

NCBI chr 1:161,134,640...161,138,964
Ensembl chr 1:151,723,086...151,728,075

G

thioredoxin reductase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:20,830,045...20,907,863

(S)-glaucine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases activity

glaucine results in increased activity of ABCB1 protein

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

(S)-magnoflorine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

collagen type II alpha 1 chain

multiple interactions

[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of phenylpyruvic acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Citric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Succinic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]

NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:129,098,786...129,127,546

G

interleukin 1 beta

multiple interactions

[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

apomorphine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

amylase 2a3

multiple interactions

Apomorphine results in increased secretion of and results in increased activity of AMY1A protein; Atenolol inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]; Metoclopramide inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]

NCBI chr 2:204,005,840...204,014,412
Ensembl chr 2:201,317,920...201,326,532

G

arginine vasopressin

increases expression
multiple interactions

Apomorphine results in increased expression of AVP protein
Metoclopramide inhibits the reaction [Apomorphine results in increased expression of AVP protein]

NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:117,793,457...117,795,425

G

bone morphogenetic protein 6

multiple interactions

Apomorphine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Apomorphine inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]

NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,318,569...26,470,365

G

bone morphogenetic protein receptor type 1A

decreases expression

Apomorphine results in decreased expression of BMPR1A mRNA

NCBI chr16:9,740,751...9,786,861
Ensembl chr16:9,736,630...9,780,616

G

cholecystokinin

multiple interactions
decreases activity

Naloxone inhibits the reaction [CCK protein results in decreased activity of Apomorphine]

NCBI chr 8:130,031,012...130,037,702
Ensembl chr 8:121,153,500...121,160,084

G

cholecystokinin B receptor

affects response to substance

CCKBR protein affects the susceptibility to Apomorphine

NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:159,771,733...159,814,881

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Apomorphine results in decreased activity of CYP1B1 protein

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917

G

dopamine receptor D1

multiple interactions

Apomorphine binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [Apomorphine results in increased activity of DRD1 protein]
[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]

PMID:8103921 PMID:15985612

NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

multiple interactions
affects response to substance
increases response to substance

[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]
Risperidone inhibits the reaction [Apomorphine binds to and results in increased activity of DRD2 protein]
DRD2 protein affects the susceptibility to Apomorphine
DRD2 protein results in increased susceptibility to Apomorphine

PMID:2571179 PMID:7520908 PMID:8103596 PMID:8103921 PMID:14639100 More...

NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D3

increases response to substance

DRD3 protein results in increased susceptibility to Apomorphine

NCBI chr11:70,385,586...70,437,793
Ensembl chr11:56,879,689...56,940,596

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Apomorphine results in increased expression of FOS protein

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036

G

furin (paired basic amino acid cleaving enzyme)

decreases expression

Apomorphine results in decreased expression of FURIN mRNA

NCBI chr 1:143,757,389...143,770,430
Ensembl chr 1:134,348,144...134,364,314

G

glial cell derived neurotrophic factor

multiple interactions

GDNF protein affects the susceptibility to [Apomorphine co-treated with Oxidopamine]

NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:56,895,010...56,917,209

G

growth hormone 1

increases secretion
increases expression

Apomorphine results in increased secretion of GH1 protein
Apomorphine results in increased expression of GH1 protein

PMID:993808 PMID:8889285

NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,228,103...91,230,078

G

hepcidin antimicrobial peptide

multiple interactions
decreases secretion
decreases expression

Apomorphine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Apomorphine inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]; Apomorphine inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA]
Apomorphine results in decreased secretion of HAMP protein modified form
Apomorphine results in decreased expression of HAMP mRNA

NCBI chr 1:95,298,332...95,300,271
Ensembl chr 1:86,170,901...86,172,891

G

5-hydroxytryptamine receptor 1A

multiple interactions

[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; [8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]; tertatolol inhibits the reaction [[8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]

NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:36,694,174...36,695,442

G

5-hydroxytryptamine receptor 6

increases response to substance
multiple interactions

HTR6 protein results in increased susceptibility to Apomorphine
Ro4368554 inhibits the reaction [HTR6 protein results in increased susceptibility to Apomorphine]

NCBI chr 5:156,579,901...156,595,147
Ensembl chr 5:151,296,662...151,311,912

G

interleukin 6

multiple interactions

Apomorphine inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Apomorphine inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein]

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656

G

ornithine decarboxylase 1

increases activity

Apomorphine results in increased activity of ODC1 protein

NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:40,329,964...40,336,440

G

proenkephalin

multiple interactions

Apomorphine inhibits the reaction [Reserpine results in increased expression of PENK mRNA]

NCBI chr 5:21,981,381...21,987,074
Ensembl chr 5:17,183,806...17,189,129

G

prolactin

decreases expression

Apomorphine results in decreased expression of PRL protein

NCBI chr17:38,287,355...38,298,234
Ensembl chr17:37,860,007...37,870,062

G

parvalbumin

affects expression

Apomorphine affects the expression of PVALB protein

NCBI chr 7:111,653,820...111,668,469
Ensembl chr 7:109,772,593...109,784,561

G

regulator of G-protein signaling 9

affects response to substance

RGS9 affects the susceptibility to Apomorphine

NCBI chr10:94,696,556...94,770,387
Ensembl chr10:94,197,054...94,270,892

G

sonic hedgehog signaling molecule

multiple interactions

SHH protein modified form affects the susceptibility to [Apomorphine co-treated with Oxidopamine]

NCBI chr 4:7,687,872...7,697,025
Ensembl chr 4:6,954,017...6,963,170

G

solute carrier family 22 member 2

multiple interactions

Apomorphine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:48,121,061...48,163,268

G

somatostatin

affects secretion

Apomorphine affects the secretion of SST protein

NCBI chr11:90,461,546...90,462,823
Ensembl chr11:76,956,896...76,958,173

G

synaptotagmin 7

multiple interactions

[Reserpine co-treated with Apomorphine] results in increased expression of SYT7 mRNA

NCBI chr 1:216,456,148...216,518,718
Ensembl chr 1:207,031,592...207,089,026

G

tachykinin, precursor 1

multiple interactions

Apomorphine promotes the reaction [Reserpine results in increased expression of TAC1 mRNA]

NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:35,679,704...35,687,178

Berbamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Bcl2-like 1

decreases expression

berbamine results in decreased expression of BCL2L1 protein

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

BH3 interacting domain death agonist

decreases expression

berbamine results in decreased expression of BID protein

NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:154,113,198...154,134,720

G

baculoviral IAP repeat-containing 5

decreases expression
affects binding

berbamine results in decreased expression of BIRC5 mRNA; berbamine results in decreased expression of BIRC5 protein
berbamine binds to BIRC5 promoter

PMID:17531122 PMID:17968851 PMID:19960011

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380

G

caspase 3

increases activity

berbamine results in increased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

cyclin D1

decreases expression

berbamine results in decreased expression of CCND1 protein

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602

G

component of inhibitor of nuclear factor kappa B kinase complex

decreases expression

berbamine results in decreased expression of CHUK protein

NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:242,959,760...242,995,065

G

NFKB inhibitor alpha

decreases phosphorylation

berbamine results in decreased phosphorylation of NFKBIA protein

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941

G

RELA proto-oncogene, NF-kB subunit

affects localization

berbamine affects the localization of RELA protein

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484

G

TNF alpha induced protein 3

increases expression

berbamine results in increased expression of TNFAIP3 protein

NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:13,709,206...13,725,282

bicuculline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activity-regulated cytoskeleton-associated protein

multiple interactions

Bicuculline inhibits the reaction [Propofol results in decreased expression of ARC protein]

NCBI chr 7:108,444,959...108,448,413
Ensembl chr 7:106,555,785...106,559,378

G

caspase 3

multiple interactions

[Bicuculline co-treated with Ethanol] results in increased cleavage of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

cAMP responsive element binding protein 1

increases phosphorylation

Bicuculline results in increased phosphorylation of CREB1 protein

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

[Bicuculline co-treated with Ethanol] results in increased phosphorylation of ERN1 protein

NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,330,654...91,421,029

G

gamma-aminobutyric acid type A receptor subunit alpha 1

multiple interactions
decreases expression

Bicuculline inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB1 protein]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]]
Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]; Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]
Bicuculline results in decreased expression of GABRA1 mRNA

PMID:1977069 PMID:9600394 PMID:27720918 PMID:29038840

NCBI chr10:27,096,731...27,152,563
Ensembl chr10:26,595,160...26,650,864

G

gamma-aminobutyric acid type A receptor subunit alpha 2

multiple interactions

Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]

NCBI chr14:37,451,218...37,587,458
Ensembl chr14:37,097,279...37,228,944

G

gamma-aminobutyric acid type A receptor subunit alpha6

multiple interactions

Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]]
Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]

PMID:27720918 PMID:29038840

NCBI chr10:27,311,965...27,327,337
Ensembl chr10:26,810,423...26,825,769

G

gamma-aminobutyric acid type A receptor subunit beta1

multiple interactions

Bicuculline inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB1 protein]]
Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]

PMID:1977069 PMID:29038840

NCBI chr14:36,434,339...36,917,920
Ensembl chr14:36,080,393...36,548,948

G

gamma-aminobutyric acid type A receptor subunit beta 2

multiple interactions

Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]]
Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]

PMID:27720918 PMID:29038840

NCBI chr10:27,438,127...27,657,680
Ensembl chr10:26,936,551...27,151,251

G

gamma-aminobutyric acid type A receptor subunit beta 3

decreases expression
multiple interactions

Bicuculline results in decreased expression of GABRB3 mRNA
Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]

PMID:9600394 PMID:29038840

NCBI chr 1:117,602,772...117,838,230
Ensembl chr 1:108,296,124...108,698,961

G

gamma-aminobutyric acid type A receptor subunit gamma 1

decreases expression

Bicuculline results in decreased expression of GABRG1 mRNA

NCBI chr14:37,750,292...37,821,651
Ensembl chr14:37,396,294...37,635,956

G

gamma-aminobutyric acid type A receptor subunit gamma 2

multiple interactions

Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]]
Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]; Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]

PMID:27720918 PMID:29038840

NCBI chr10:26,876,926...26,965,523
Ensembl chr10:26,374,694...26,464,346

G

gonadotropin releasing hormone 1

multiple interactions

Bicuculline affects the reaction [bisphenol A affects the secretion of GNRH1 protein]; Bicuculline promotes the reaction [manganese chloride results in increased secretion of GNRH1 protein]

PMID:18603625 PMID:26950200

NCBI chr15:46,147,878...46,152,086
Ensembl chr15:41,972,905...41,973,581
Ensembl chr15:41,972,905...41,973,581

G

glutamic--pyruvic transaminase

multiple interactions

Bicuculline promotes the reaction [Ethanol results in increased activity of GPT protein]

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494

G

glutamate ionotropic receptor AMPA type subunit 1

multiple interactions
decreases expression

Bicuculline results in decreased expression of and results in decreased localization of GRIA1 protein
Bicuculline decreases expression of Gria1 protein in nucleus accumbens cultured cells
Bicuculline decreases expression of Gria1 protein on nucleus accumbens medium spiny neurons

CTD
RGD

PMID:19674091 PMID:19674091 PMID:24712995

RGD:4107725, RGD:405650624

NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,210,713...41,527,283

G

glutamate ionotropic receptor AMPA type subunit 2

multiple interactions
decreases expression

Bicuculline promotes the reaction [MECP2 protein binds to GRIA2 promoter]; Bicuculline results in decreased expression of and results in decreased localization of GRIA2 protein; MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein]
Bicuculline decreases expression of Gria2 protein on nucleus accumbens medium spiny neurons
Bicuculline decreases expression of Gria2 protein in nucleus accumbens cultured cells
Bicuculline results in decreased expression of GRIA2 mRNA; Bicuculline results in decreased expression of GRIA2 protein

CTD
RGD

PMID:19674091 PMID:22262897 PMID:24712995 PMID:19674091

RGD:405650624, RGD:4107725

NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:165,947,521...166,069,510

G

glutamate ionotropic receptor NMDA type subunit 2D

multiple interactions

[Bicuculline co-treated with 4-Aminopyridine] results in decreased expression of GRIN2D protein

NCBI chr 1:105,443,317...105,483,400
Ensembl chr 1:96,308,365...96,344,793

G

histone deacetylase 5

multiple interactions

[Bicuculline co-treated with 4-Aminopyridine] affects the localization of HDAC5 protein

NCBI chr10:87,653,139...87,688,078
Ensembl chr10:87,152,978...87,188,235

G

mitogen-activated protein kinase kinase kinase 5

multiple interactions

[Bicuculline co-treated with Ethanol] results in increased expression of MAP3K5 protein

NCBI chr 1:16,505,387...16,723,899
Ensembl chr 1:14,685,492...14,904,800

G

mitogen activated protein kinase 1

multiple interactions

Bicuculline inhibits the reaction [methyl tert-butyl ether results in decreased phosphorylation of MAPK1 protein]
[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein]

PMID:19344668 PMID:19911010

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Bicuculline inhibits the reaction [methyl tert-butyl ether results in decreased phosphorylation of MAPK3 protein]
[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein]

PMID:19344668 PMID:19911010

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

[Bicuculline co-treated with Ethanol] results in increased expression of MAPK8 protein

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981

G

methyl CpG binding protein 2

multiple interactions
increases phosphorylation
increases expression

MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein]
Bicuculline promotes the reaction [MECP2 protein binds to GRIA2 promoter]; MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein]
Bicuculline results in increased phosphorylation of MECP2 protein
Bicuculline results in increased expression of MECP2 mRNA

NCBI chr X:156,932,481...156,995,981
Ensembl chr X:151,789,930...151,844,689

G

multiple PDZ domain crumbs cell polarity complex component

affects response to substance

MPDZ protein affects the susceptibility to Bicuculline

NCBI chr 5:100,812,121...100,966,566
Ensembl chr 5:95,766,118...95,920,499

G

nuclear receptor co-repressor 2

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; [Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]

NCBI chr12:37,127,736...37,289,612
Ensembl chr12:31,466,412...31,628,319

G

nerve growth factor

multiple interactions

Bicuculline inhibits the reaction [Propofol inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]]; Bicuculline inhibits the reaction [Thiopental inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]]

NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:189,901,058...189,954,452

G

oxytocin receptor

multiple interactions

Bicuculline inhibits the reaction [oxytocin, Thr(4)-Gly(7)- results in increased activity of OXTR protein]

NCBI chr 4:147,154,374...147,171,723
Ensembl chr 4:145,599,561...145,614,674

G

retinoic acid receptor, alpha

multiple interactions

[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]

NCBI chr10:84,379,780...84,424,371
Ensembl chr10:83,893,384...83,928,142

G

ryanodine receptor 1

increases response to substance

RYR1 results in increased susceptibility to Bicuculline

NCBI chr 1:93,420,078...93,551,305
Ensembl chr 1:84,292,578...84,423,812

G

ryanodine receptor 2

increases response to substance

RYR2 results in increased susceptibility to Bicuculline

NCBI chr17:63,081,527...63,667,141
Ensembl chr17:58,389,925...58,975,142

G

tyrosine hydroxylase

multiple interactions

Bicuculline promotes the reaction [Reserpine affects the activity of TH protein]; Bicuculline promotes the reaction [Reserpine results in increased expression of TH mRNA]

NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:198,071,503...198,109,767

Boldine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

increases expression

boldine results in increased expression of ABCB11 mRNA; boldine results in increased expression of ABCB11 protein

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 2

increases expression

boldine results in increased expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238

G

actin alpha 2, smooth muscle

multiple interactions

boldine inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

aquaporin 8

increases expression

boldine results in increased expression of AQP8 mRNA

NCBI chr 1:187,424,314...187,430,243
Ensembl chr 1:177,993,305...177,999,158

G

catalase

multiple interactions

boldine inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased activity of CAT protein]
boldine inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]

PMID:32531310 PMID:38500399

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

dopamine receptor D1

affects binding
multiple interactions

boldine analog binds to DRD1 protein
boldine analog inhibits the reaction [SCH 23390 binds to DRD1 protein]

NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,540,558...10,545,002

G

glutamic--pyruvic transaminase

multiple interactions

boldine inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein]

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494

G

interleukin 1 beta

multiple interactions

boldine inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B mRNA]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

myeloperoxidase

multiple interactions

boldine inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased activity of MPO protein]

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819

G

nuclear factor kappa B subunit 1

multiple interactions

boldine inhibits the reaction [Carbon Tetrachloride results in increased expression of NFKB1 mRNA]

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404

G

nuclear receptor subfamily 0, group B, member 2

increases expression

boldine results in increased expression of NR0B2 mRNA

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group H, member 4

increases expression

boldine results in increased expression of NR1H4 mRNA

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:23,846,122...23,942,047

G

prostaglandin-endoperoxide synthase 2

multiple interactions

boldine inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 mRNA]

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188

G

solute carrier family 4 member 2

increases expression

boldine results in increased expression of SLC4A2 mRNA

NCBI chr 4:11,628,860...11,646,961
Ensembl chr 4:10,736,425...10,752,965

G

telomerase reverse transcriptase

affects splicing
decreases activity

boldine affects the splicing of TERT mRNA
boldine results in decreased activity of TERT protein

NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:29,637,506...29,659,561

G

tumor necrosis factor

multiple interactions

boldine inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased expression of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

UDP glucuronosyltransferase family 1 member A1

increases expression

boldine results in increased expression of UGT1A1 mRNA

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:88,713,184...88,808,465

cepharanthine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity

cepharanthine results in decreased activity of ABCB1 protein

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

G

potassium voltage-gated channel subfamily H member 2

decreases activity

cepharanthine results in decreased activity of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008

G

MCL1 apoptosis regulator, BCL2 family member

increases expression

cepharanthine results in increased expression of MCL1 protein

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:183,219,220...183,222,303

G

mechanistic target of rapamycin kinase

decreases expression

cepharanthine results in decreased expression of MTOR protein

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311

G

poly (ADP-ribose) polymerase 1

decreases expression

cepharanthine results in decreased expression of PARP1 protein

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

tumor protein p53

increases expression

cepharanthine results in increased expression of TP53 protein

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

dauricine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases glutathionylation
multiple interactions

CYP3A4 protein results in increased glutathionylation of dauricine
[CYP3A4 protein results in increased glutathionylation of dauricine] which results in increased chemical synthesis of N-desmethyldauricine; [CYP3A4 protein results in increased glutathionylation of dauricine] which results in increased chemical synthesis of quinone methide; CYP3A4 protein results in increased oxidation of and results in increased activity of dauricine; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased glutathionylation of dauricine]

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008

fangchinoline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activating transcription factor 4

increases expression
multiple interactions

fangchinoline results in increased expression of ATF4 protein
Acetylcysteine inhibits the reaction [fangchinoline results in increased expression of ATF4 protein]

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:111,804,183...111,806,446

G

baculoviral IAP repeat-containing 5

decreases expression

fangchinoline results in decreased expression of BIRC5 mRNA; fangchinoline results in decreased expression of BIRC5 protein

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380

G

caspase 3

increases cleavage

fangchinoline results in increased cleavage of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases cleavage

fangchinoline results in increased cleavage of CASP8 protein

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542

G

cathepsin D

decreases expression

fangchinoline results in decreased expression of CTSD protein

NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:197,527,467...197,539,488

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

fangchinoline results in increased expression of DDIT3 protein
Acetylcysteine inhibits the reaction [fangchinoline results in increased expression of DDIT3 protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

heat shock protein family A (Hsp70) member 5

increases expression
multiple interactions

fangchinoline results in increased expression of HSPA5 protein
Acetylcysteine inhibits the reaction [fangchinoline results in increased expression of HSPA5 protein]

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891

G

microtubule-associated protein 1 light chain 3 alpha

increases lipidation

fangchinoline results in increased lipidation of MAP1LC3A protein

NCBI chr 3:164,243,204...164,244,850
Ensembl chr 3:143,783,024...143,784,670

G

microtubule-associated protein 1 light chain 3 beta

increases lipidation

fangchinoline results in increased lipidation of MAP1LC3B protein

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen-activated protein kinase 8

multiple interactions

[fangchinoline co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981

G

poly (ADP-ribose) polymerase 1

increases cleavage

fangchinoline results in increased cleavage of PARP1 protein

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

sequestosome 1

increases expression

fangchinoline results in increased expression of SQSTM1 protein

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673

norlaudanosoline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases phosphorylation

Tetrahydropapaveroline increases phosphorylation of Akt1 protein in PC12 cells

RGD

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 2 family member

multiple interactions

[[CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline] inhibits the reaction [Cocaine results in increased abundance of and results in increased secretion of Dopamine]; [ALDH2 protein affects the abundance of Tetrahydropapaveroline] which affects the susceptibility to Cocaine; [CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline

NCBI chr12:40,610,244...40,643,220
Ensembl chr12:34,901,219...34,982,521

G

interleukin 1 beta

multiple interactions

Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

tumor necrosis factor

multiple interactions

Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

papaverine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin converting enzyme 2

decreases expression

Papaverine results in decreased expression of ACE2 mRNA

NCBI chr X:33,925,458...33,972,851
Ensembl chr X:30,293,589...30,340,977

G

brain-derived neurotrophic factor

increases expression

Papaverine results in increased expression of BDNF mRNA

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615

G

CF transmembrane conductance regulator

multiple interactions
increases activity

Papaverine promotes the reaction [CFTR protein affects the secretion of Chlorides]
Papaverine results in increased activity of CFTR protein

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756

G

claudin 5

decreases expression

Papaverine results in decreased expression of CLDN5 protein

NCBI chr11:95,717,172...95,718,598
Ensembl chr11:82,211,475...82,214,992

G

cAMP responsive element binding protein 1

increases expression

Papaverine results in increased expression of CREB1 mRNA

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Papaverine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

Papaverine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312

G

hepcidin antimicrobial peptide

decreases expression

Papaverine results in decreased expression of HAMP mRNA

NCBI chr 1:95,298,332...95,300,271
Ensembl chr 1:86,170,901...86,172,891

G

heat shock transcription factor 1

increases activity

Papaverine results in increased activity of HSF1 protein

NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:108,196,056...108,223,011

G

lipase E, hormone sensitive type

multiple interactions

Papaverine inhibits the reaction [Isoproterenol affects the localization of LIPE protein]; Papaverine inhibits the reaction [Isoproterenol results in increased activity of LIPE protein]

NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:80,965,627...80,984,310

G

nuclear receptor subfamily 1, group H, member 4

increases activity

Papaverine results in increased activity of NR1H4 protein

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:23,846,122...23,942,047

G

neurotrophic receptor tyrosine kinase 2

increases expression

Papaverine results in increased expression of NTRK2 mRNA

NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,559,043...5,869,136

G

occludin

decreases expression

Papaverine results in decreased expression of OCLN protein

NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:31,657,220...31,764,150

G

phosphodiesterase 7A

multiple interactions

Papaverine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]

NCBI chr 2:103,631,655...103,723,057
Ensembl chr 2:101,718,444...101,806,681

G

phosphodiesterase 7B

multiple interactions

Papaverine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]

NCBI chr 1:16,994,072...17,312,828
Ensembl chr 1:15,182,704...15,492,900

G

solute carrier family 22 member 3

multiple interactions

Papaverine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]
Papaverine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Papaverine inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]

PMID:9830022 PMID:12411423

NCBI chr 1:50,783,218...50,872,358
Ensembl chr 1:48,235,476...48,324,612

tubocurarine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

Tubocurarine promotes the reaction [Dichlorvos results in increased phosphorylation of ACHE protein]; Tubocurarine promotes the reaction [haloxon results in increased phosphorylation of ACHE protein]; Tubocurarine promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein]

NCBI chr12:25,042,882...25,050,608
Ensembl chr12:19,407,360...19,413,651

G

amyloid beta precursor protein

multiple interactions

Tubocurarine inhibits the reaction [[Nicotine results in increased metabolism of APP protein] which results in increased secretion of APP protein modified form]; Tubocurarine inhibits the reaction [Nicotine results in increased metabolism of APP protein]

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561

G

BCL2, apoptosis regulator

multiple interactions

Tubocurarine inhibits the reaction [PTMA protein results in decreased expression of BCL2]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone gamma-carboxyglutamate protein

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in increased expression of BGLAP]

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:173,838,518...173,839,495

G

complement C7

multiple interactions
decreases expression

Tubocurarine inhibits the reaction [Nicotine results in increased expression of C7 mRNA]
Tubocurarine results in decreased expression of C7 mRNA

NCBI chr 2:55,815,687...55,892,605
Ensembl chr 2:54,088,116...54,158,535

G

cyclin-dependent kinase 4

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in decreased expression of CDK4 protein]

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403

G

cholinergic receptor nicotinic alpha 1 subunit

multiple interactions

Tubocurarine inhibits the reaction [CHRNA1 protein binds to PLAU protein]

NCBI chr 3:78,862,286...78,877,353
Ensembl chr 3:58,454,744...58,469,840

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

Tubocurarine inhibits the reaction [Acetylcholine binds to and results in increased activity of [CHRNB2 protein binds to CHRNA2 protein]]; Tubocurarine promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]]

NCBI chr15:44,517,862...44,534,144
Ensembl chr15:40,342,317...40,358,601

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]; Tubocurarine inhibits the reaction [desnitroimidacloprid results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
Tubocurarine inhibits the reaction [Acetylcholine binds to and results in increased activity of [CHRNB2 protein binds to CHRNA3 protein]]; Tubocurarine promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]]; Tubocurarine results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]

PMID:7808438 PMID:9687574 PMID:16931985 PMID:34628512

NCBI chr 8:64,297,755...64,311,251
Ensembl chr 8:55,401,702...55,415,165

G

cholinergic receptor nicotinic alpha 4 subunit

multiple interactions

Tubocurarine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Ethinyl Estradiol promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]]; Tubocurarine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]

PMID:7756618 PMID:11711029 PMID:14645658 PMID:16931985

NCBI chr 3:188,506,802...188,535,558
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

Tubocurarine binds to and results in decreased activity of CHRNA7 protein; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein]; Tubocurarine inhibits the reaction [Bungarotoxins binds to CHRNA7 protein]

PMID:10082212 PMID:10216184 PMID:16931985

NCBI chr 1:126,123,425...126,249,181
Ensembl chr 1:116,714,711...116,837,240

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Tubocurarine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Ethinyl Estradiol promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]]; Tubocurarine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
Tubocurarine inhibits the reaction [Acetylcholine binds to and results in increased activity of [CHRNB2 protein binds to CHRNA2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine binds to and results in increased activity of [CHRNB2 protein binds to CHRNA3 protein]]
Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein]

PMID:7756618 PMID:7808438 PMID:11711029 PMID:14645658 PMID:16931985

NCBI chr 2:177,479,091...177,487,306
Ensembl chr 2:175,181,402...175,189,619

G

cholinergic receptor nicotinic beta 4 subunit

multiple interactions

Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]; Tubocurarine inhibits the reaction [desnitroimidacloprid results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
Tubocurarine promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]]; Tubocurarine promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]]; Tubocurarine results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]

PMID:7808438 PMID:9687574 PMID:16931985 PMID:34628512

NCBI chr 8:64,312,644...64,333,319
Ensembl chr 8:55,418,313...55,437,027

G

contactin 1

increases expression
decreases expression
multiple interactions

Tubocurarine results in increased expression of CNTN1 mRNA
Tubocurarine results in decreased expression of CNTN1 mRNA
Tubocurarine inhibits the reaction [Nicotine results in decreased expression of CNTN1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of CNTN1 mRNA]

PMID:12588870 PMID:16949557

NCBI chr 7:125,142,638...125,440,397
Ensembl chr 7:123,372,792...123,558,541

G

colony stimulating factor 2

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in increased secretion of CSF2 protein]

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,386,945...38,389,199

G

dihydrofolate reductase

multiple interactions
decreases expression

Tubocurarine inhibits the reaction [Nicotine results in decreased expression of DHFR mRNA]
Tubocurarine results in decreased expression of DHFR mRNA

NCBI chr 2:25,320,895...25,346,004
Ensembl chr 2:23,586,031...23,613,713

G

EMAP like 4

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in decreased expression of EML4 mRNA]

NCBI chr 6:16,972,054...17,087,365
Ensembl chr 6:11,219,566...11,334,879

G

Fas cell surface death receptor

multiple interactions

Tubocurarine inhibits the reaction [PTMA protein results in increased expression of FAS]

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591

G

fasciculation and elongation protein zeta 1

multiple interactions
decreases expression

Tubocurarine promotes the reaction [Nicotine results in decreased expression of FEZ1 mRNA]
Tubocurarine results in decreased expression of FEZ1 mRNA

NCBI chr 8:44,733,288...44,778,519
Ensembl chr 8:36,544,535...36,589,683

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in increased expression of FOS]

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036

G

golgin A4

decreases expression
multiple interactions

Tubocurarine results in decreased expression of GOLGA4 mRNA
Tubocurarine inhibits the reaction [Nicotine results in increased expression of GOLGA4 mRNA]

NCBI chr 8:127,085,830...127,163,227

G

interleukin 1 beta

multiple interactions

Tubocurarine inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 mRNA]]; Tubocurarine inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased secretion of CXCL8 protein]]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

potassium calcium-activated channel subfamily N member 1

decreases activity

Tubocurarine results in decreased activity of KCNN1 protein

NCBI chr16:18,608,782...18,632,571
Ensembl chr16:18,585,992...18,597,482

G

potassium calcium-activated channel subfamily N member 2

decreases activity

Tubocurarine results in decreased activity of KCNN2 protein

PMID:10696100 PMID:10991935

NCBI chr18:40,004,693...40,445,043
Ensembl chr18:37,817,957...38,258,347

G

lysine methyltransferase 2C

multiple interactions
decreases expression

Tubocurarine inhibits the reaction [Nicotine results in decreased expression of KMT2C mRNA]
Tubocurarine results in decreased expression of KMT2C mRNA

NCBI chr 4:10,353,698...10,755,965
Ensembl chr 4:9,609,627...9,833,539

G

lipopolysaccharide-induced TNF factor

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in decreased expression of LITAF mRNA]

NCBI chr10:5,163,258...5,199,930
Ensembl chr10:4,625,552...4,692,763

G

mitogen activated protein kinase 1

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 1

multiple interactions

Tubocurarine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP1 protein]]; Tubocurarine inhibits the reaction [Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP1 protein]]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of MMP1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of MMP1 protein]

PMID:17151781 PMID:18986645

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:4,658,588...4,679,097

G

ninein

multiple interactions
decreases expression

Tubocurarine inhibits the reaction [Nicotine results in increased expression of NIN mRNA]
Tubocurarine results in decreased expression of NIN mRNA

NCBI chr 6:94,261,382...94,363,679
Ensembl chr 6:88,525,742...88,627,639

G

plasminogen activator, urokinase

multiple interactions

Tubocurarine inhibits the reaction [CHRNA1 protein binds to PLAU protein]

NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,456,232...3,462,775

G

POU class 5 homeobox 1

decreases expression
multiple interactions

Tubocurarine results in decreased expression of POU5F1 mRNA
Tubocurarine inhibits the reaction [Nicotine results in increased expression of POU5F1 mRNA]

PMID:15612475 PMID:15749260

NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,223,129...3,227,891

G

parkin RBR E3 ubiquitin protein ligase

decreases expression

Tubocurarine results in decreased expression of PRKN mRNA

NCBI chr 1:51,236,410...52,430,242
Ensembl chr 1:48,690,556...49,882,555

G

prothymosin alpha

multiple interactions

Tubocurarine inhibits the reaction [PTMA protein results in decreased expression of BCL2]; Tubocurarine inhibits the reaction [PTMA protein results in increased expression of FAS]

NCBI chr 9:94,624,194...94,628,276
Ensembl chr 9:87,176,230...87,180,333

G

protein tyrosine phosphatase, receptor type, A

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in decreased expression of PTPRA mRNA]

NCBI chr 3:138,103,261...138,212,835
Ensembl chr 3:117,650,183...117,759,728

G

RB binding protein 6, ubiquitin ligase

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in decreased expression of RBBP6 mRNA]

NCBI chr 1:186,934,563...186,966,852
Ensembl chr 1:177,503,313...177,535,678

G

surfactant protein A1

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in increased expression of SFTPA1 mRNA]

NCBI chr16:17,042,264...17,045,770
Ensembl chr16:17,008,180...17,011,685

G

surfactant protein C

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in increased expression of SFTPC mRNA]

NCBI chr15:52,006,274...52,009,324
Ensembl chr15:45,596,574...45,610,777

G

SOS Ras/Rac guanine nucleotide exchange factor 1

multiple interactions
decreases expression

Tubocurarine inhibits the reaction [Nicotine results in increased expression of SOS1 mRNA]
Tubocurarine results in decreased expression of SOS1 mRNA

NCBI chr 6:20,286,117...20,363,350
Ensembl chr 6:14,533,360...14,611,107

G

secreted phosphoprotein 1

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in increased expression of SPP1 protein]

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162

G

stress-induced phosphoprotein 1

multiple interactions
decreases expression

Tubocurarine inhibits the reaction [Nicotine results in decreased expression of STIP1 mRNA]
Tubocurarine results in decreased expression of STIP1 mRNA

NCBI chr 1:213,638,641...213,657,654
Ensembl chr 1:204,178,932...204,228,476

G

ubiquitin-conjugating enzyme E2C

multiple interactions
decreases expression

Tubocurarine inhibits the reaction [Nicotine results in decreased expression of UBE2C mRNA]
Tubocurarine results in decreased expression of UBE2C mRNA

NCBI chr 3:173,925,975...173,928,375
Ensembl chr 3:153,506,636...153,513,339

G

ubiquitin protein ligase E3A

increases expression
multiple interactions

Tubocurarine results in increased expression of UBE3A mRNA
Tubocurarine inhibits the reaction [Nicotine results in decreased expression of UBE3A mRNA]

NCBI chr 1:119,204,244...119,297,097
Ensembl chr 1:110,070,480...110,157,250

G

xanthine dehydrogenase

multiple interactions

Tubocurarine inhibits the reaction [Isoflurophate results in increased expression of XDH protein alternative form]

NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:21,530,113...21,592,268

G

zinc finger protein 42

multiple interactions

Tubocurarine inhibits the reaction [Nicotine results in increased expression of ZFP42 mRNA]

NCBI chr16:55,568,903...55,577,883
Ensembl chr16:48,836,648...48,845,401
Ensembl chr 4:48,836,648...48,845,401

G

zinc finger RNA binding protein

decreases expression
multiple interactions

Tubocurarine results in decreased expression of ZFR mRNA
Tubocurarine inhibits the reaction [Nicotine results in decreased expression of ZFR mRNA]

NCBI chr 2:62,864,333...62,927,377
Ensembl chr 2:61,137,611...61,200,322

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19909
role	19880
biological role	19878
biochemical role	19586
metabolite	19573
alkaloid	8034
isoquinoline alkaloid	1205
benzylisoquinoline alkaloid	223
(-)-noscapine	12
(-)-noscapine hemiacetal +	12
(R)-laudanosine	0
(S)-codamine	0
(S)-tembetarine	0
1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline +	0
3-O-acetyl-4'-O-demethylpapaveroxine +	0
3-O-acetylpapaveroxine	0
aporphine alkaloid +	47
berbaman	0
bicuculline	31
bisbenzylisoquinoline alkaloid +	119
coclaurine +	26
laudanine +	0
norcoclaurine +	26
norlaudanosoline +	5
norreticuline +	0
papaverine	16
parfumine	0
perquinoline	0
reticuline +	0
reticulinylium	0
tubocuraran +	46
Path 2
Term	Annotations
CHEBI ontology	19909
subatomic particle	19907
composite particle	19907
hadron	19907
baryon	19907
nucleon	19907
atomic nucleus	19907
atom	19907
main group element atom	19846
main group molecular entity	19846
p-block molecular entity	19846
carbon group molecular entity	19784
organic molecular entity	19781
heteroorganic entity	19540
organonitrogen compound	18858
alkaloid	8034
isoquinoline alkaloid	1205
benzylisoquinoline alkaloid	223
(-)-noscapine	12
(-)-noscapine hemiacetal +	12
(R)-laudanosine	0
(S)-codamine	0
(S)-tembetarine	0
1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline +	0
3-O-acetyl-4'-O-demethylpapaveroxine +	0
3-O-acetylpapaveroxine	0
aporphine alkaloid +	47
berbaman	0
bicuculline	31
bisbenzylisoquinoline alkaloid +	119
coclaurine +	26
laudanine +	0
norcoclaurine +	26
norlaudanosoline +	5
norreticuline +	0
papaverine	16
parfumine	0
perquinoline	0
reticuline +	0
reticulinylium	0
tubocuraran +	46

paths to the root